As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

and build our commercial business," said Bancel. In the near term, that means driving uptake of Moderna's Spikevax COVID-19 vaccines and recently-approved mResvia for respiratory syncytial virus ...

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The pandemic accelerated Moderna's evolution into a commercial-stage biotech, and we expect that the firm's ramp-up in manufacturing and clinical know-how will pave the way for faster timelines ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

All commercial poultry operations located within ... and ensure that Americans have the tools they need to stay safe." Moderna's influenza vaccine uses mRNA technology used during the COVID ...

Moderna (NASDAQ: MRNA ... That seems like a very reasonable price when you consider commercial-stage biotech stocks tend to trade for mid-single-digit multiples of trailing-12-month sales.

This diverse pipeline exemplifies Moderna's road map to extend its mRNA technology into new categories, positioning itself as a more diversified and mature commercial-stage biotech company.

Moderna enters 2025 with a focus on a prioritized ... and the potential and timing for future product approvals, data readouts and commercial launches. In some cases, forward-looking statements ...

it is clear that the past year brought formidable challenges for Moderna along with significant advances, particularly for our development pipeline. It was a year of navigating a dynamic global ...